Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Atara Biotherapeutics stock | 19.53

Own Atara Biotherapeutics stock in just a few minutes.

Posted

Fact checked

Atara Biotherapeutics, Inc is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Atara Biotherapeutics employs 425 staff and has a market cap (total outstanding shares value) of USD$1 billion.

How to buy shares in Atara Biotherapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Atara Biotherapeutics. Find the stock by name or ticker symbol: ATRA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Atara Biotherapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$19.53, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Atara Biotherapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Atara Biotherapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Atara Biotherapeutics's share price?

Since the stock market crash in March caused by coronavirus, Atara Biotherapeutics's share price has had significant positive movement.

Its last market close was USD$19.53, which is 32.46% up on its pre-crash value of USD$13.19 and 332.08% up on the lowest point reached during the March crash when the shares fell as low as USD$4.52.

If you had bought USD$1,000 worth of Atara Biotherapeutics shares at the start of February 2020, those shares would have been worth USD$572.18 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,416.32.

Atara Biotherapeutics share price

Use our graph to track the performance of ATRA stocks over time.

Atara Biotherapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$19.53
52-week range USD$4.52 - USD$17.94
50-day moving average USD$13.9941
200-day moving average USD$12.1355
Wall St. target price USD$28.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-6.071

Buy Atara Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Atara Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atara Biotherapeutics price performance over time

Historical closes compared with the close of $19.53 from 2020-11-16

1 week (2020-11-20) -15.01%
1 month (2020-10-30) 51.28%
3 months (2020-08-28) 43.92%
6 months (2020-05-29) 69.83%
1 year (2019-11-29) 37.44%
2 years (2018-11-29) -51.86%
3 years (2017-11-29) 38.51%
5 years (2015-11-27) -50.64%

Atara Biotherapeutics financials

Gross profit TTM USD$0
Return on assets TTM -54.27%
Return on equity TTM -98.26%
Profit margin 0%
Book value $5.129
Market capitalisation USD$1 billion

TTM: trailing 12 months

Shorting Atara Biotherapeutics shares

There are currently 14.2 million Atara Biotherapeutics shares held short by investors – that's known as Atara Biotherapeutics's "short interest". This figure is 3.3% up from 13.7 million last month.

There are a few different ways that this level of interest in shorting Atara Biotherapeutics shares can be evaluated.

Atara Biotherapeutics's "short interest ratio" (SIR)

Atara Biotherapeutics's "short interest ratio" (SIR) is the quantity of Atara Biotherapeutics shares currently shorted divided by the average quantity of Atara Biotherapeutics shares traded daily (recently around 1.1 million). Atara Biotherapeutics's SIR currently stands at 13.12. In other words for every 100,000 Atara Biotherapeutics shares traded daily on the market, roughly 13120 shares are currently held short.

However Atara Biotherapeutics's short interest can also be evaluated against the total number of Atara Biotherapeutics shares, or, against the total number of tradable Atara Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atara Biotherapeutics's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Atara Biotherapeutics shares in existence, roughly 190 shares are currently held short) or 0.2217% of the tradable shares (for every 100,000 tradable Atara Biotherapeutics shares, roughly 222 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Atara Biotherapeutics.

Find out more about how you can short Atara Biotherapeutics stock.

Atara Biotherapeutics share dividends

We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.

Atara Biotherapeutics share price volatility

Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $4.52 up to $17.94. A popular way to gauge a stock's volatility is its "beta".

ATRA.US volatility(beta: 2.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 2.0276. This would suggest that Atara Biotherapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Atara Biotherapeutics overview

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site